Evidence map›Paper›PMID 31992618›Full record

ArticlemBio2020

Plasmodium falciparum Resistance to a Lead Benzoxaborole Due to Blocked Compound Activation and Altered Ubiquitination or Sumoylation.

Kirthana M V Sindhe, Wesley Wu, Jenny Legac, Yong-Kang Zhang, Eric E Easom, Roland A Cooper, Jacob J Plattner, Yvonne R Freund, Joseph L DeRisi, Philip J Rosenthal

Open access · goldAbstract read
In one paragraph

Article in mBio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Prodrug activation in malaria parasites mediated by an imported erythrocyte esterase, acylpeptide hydrolase (APEH).Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  5. Systematic in vitro evolution inScience (New York, N.Y.) · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Kirthana M V Sindhe *Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
Wesley Wu *Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, California, USA.
Jenny LegacDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Yong-Kang ZhangAnacor Pharmaceuticals, Inc., Palo Alto, California, USA.
Eric E EasomAnacor Pharmaceuticals, Inc., Palo Alto, California, USA.
Roland A CooperDominican University of California, San Rafael, California, USA.
Jacob J PlattnerAnacor Pharmaceuticals, Inc., Palo Alto, California, USA.
Yvonne R FreundAnacor Pharmaceuticals, Inc., Palo Alto, California, USA.
Joseph L DeRisiDepartment of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0002-4611-9205
Philip J RosenthalDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA philip.rosenthal@ucsf.edu.
University of California, San Francisco · USDominican University of California · US

Funding

Discovery of Oxaboroles as New Antimalarial AgentsR01AI095324 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENTHAL, PHILIP JON · 2012 to 2016
$2.3M
Discovery of Oxaboroles as New Antimalarial AgentsR56AI095324 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENTHAL, PHILIP JON · 2011 to 2011
$718k
NIAID NIH HHS R01 AI095324NIAID NIH HHS R56 AI095324
6 · The paper itself

Abstract

New antimalarial drugs are needed. The benzoxaborole AN13762 showed excellent activity against cultured

Indexed as

Drug ResistanceAntimalarialsChromatography, LiquidDNA Mutational AnalysisHumansMalaria, FalciparumMass SpectrometryMolecular StructureMutationPlasmodium falciparumPolymorphism, Single NucleotideProtozoan ProteinsSumoylationUbiquitinationAntimalarialsProtozoan Proteinsantimalarial agentsbenzoxaboroledrugdrug resistance evolutiondrug resistance mechanismsmalariaPfPAREPlasmodium falciparumresistancesumoylationubiquitination

Identifiers

PMID31992618
PMCPMC6989105
OpenAlexW3003179697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.